343 results about "Autoantibody" patented technology

The invention relates to a magnetic particle capable of being specifically combined with an anti-Nephrin antibody in a sample. The magnetic particle comprises a magnetic bead which can be specifically combined with an anti-Nephrin autoantibody of a mammal and is coated with a polypeptide or a fragment of the polypeptide; wherein the magnetic beads are carboxyl magnetic beads; the particle size of the carboxyl magnetic beads is 1-5 [mu] m; preferably, the particle size of the carboxyl magnetic beads is 1-3 [mu] m; more preferably, the particle size of the magnetic beads is 3 microns. The anti-Nephrin antibody detection method disclosed by the invention is short in detection time, high in sensitivity, strong in specificity, stable and reliable in result, high in uniformity and easy to clinically popularize.

The invention discloses a citrullinated SAA polypeptide and application thereof in preparation of a rheumatoid arthritis diagnosis product, the amino acid sequence of the citrullinated SAA polypeptide is DKYFHA-Cit-GNYDAAK-Cit-GPGGA, through the polypeptide, the citrullinated autoantigen B cell epitope of SAA and a corresponding autoantibody, namely an anti-citrullinated SAA polypeptide antibody (anti-CAP), are identified. The expression level of anti-CAP in RA patients is obviously higher than that of other disease control groups and healthy groups, and the anti-CAP has better positive rate in early RA, ESR / CRP normal RA and anti-CCP antibody / RF negative RA, and provides a new strategy for diagnosis of RA.

The present disclosure provides inter alia, molecules comprising an autoantibody-binding domain and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic autoantibodies.

The invention belongs to the technical field of monoclonal antibody preparation, and particularly relates to a human-mouse chimeric monoclonal antibody for resisting human G protein-coupled receptor family member 1 (LGI1 protein) as well as a product and application of the human-mouse chimeric monoclonal antibody. The variable regions of the heavy chain and the light chain of the human-mouse chimeric monoclonal antibody of the anti-human LGI1 protein come from mice, and the constant regions of the heavy chain and the light chain of the human-mouse chimeric monoclonal antibody are human antibody constant regions, so that the human-mouse chimeric monoclonal antibody can replace the function of serum to a certain extent on the basis of retaining parent activity to the greatest extent; meanwhile, the technical problems that the Fc region of the existing anti-human LGI1 protein monoclonal antibody cannot react with the anti-human IgG antibody, the sensitivity difference among multiple batches of antibodies is large, and batch production cannot be realized can be solved. Furthermore, the human-mouse chimeric monoclonal antibody of the anti-human LGI1 protein can be used for detecting the LGI1 protein and an LGI1 autoantibody.

The present disclosure provides inter alia, molecules comprising an autoantibody-binding domain and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic autoantibodies.

The use of dual-target CAR-T cells in treating systemic lupus erythematosus and other B-cell autoimmune diseases is provided. The first target of the chimeric antigen receptor is CD19, the second target is BCMA, and specifically, the chimeric antigen receptor is a chimeric antigen receptor with a Loop structure, which is shown as follow: L-VL, CD19-VH, BCMA-VL, BCMA-VH, CD19-H-TM-C-CD3ζ; the BCMA-CD19 CAR-T cells transduced by the chimeric antigen receptor targeting CD19 and BCMA can completely block the pathway of producing autoantibodies, and completely cover the B cells, plasmablasts and plasma cells at multiple differentiation stages that produce autoantibodies, so that the dual-target CAR-T therapy designed based on this concept can be aimed at refractory SLE and is expected to achieve faster remission and deeper and lasting curative effect.

The present invention the invention concerns bifunctional compounds of Formula (I) A-T-L1-AG, Formula (II) A-L1-Con(L2-AG)n or Formula (III) Ak´-Th-L3 ii-AGj' wherein A is a protein that binds to the hinge region of galactose deficient IgA1 antibodies or a protein that binds to autoantibodies of galactose deficient IgA antibodies and AG is an asiaglycoprotein receptor binding moiety (ASGPR binding moiety). L1, Con and L2 are part of a linker between A and AG. The A has the ability to bind to antibodies that are a cause of IgA nephropathy and the asiaglycoprotein receptor binding moiety binds to hepatic cells thereby initiating endocytosis and removal of the antibodies that are a cause of IgA nephropathy from the blood stream.

The invention discloses a fusion protein, a fusion protein gene, a recombinant cell, a recombinant antigen, a reagent for detecting an anti-myelin sheath related glycoprotein antibody and a preparation method, a detection method and application of the reagent, the fusion protein is MAG, GlcAT-P and HNK-1ST fusion protein, and the MAG, GlcAT-P and HNK-1ST fusion protein is formed by sequentially connecting MAG, a GGGGS sequence, EGFP, P2A, GlcAT-P, T2A and HNK-1ST; the amino acid sequence of the MAG, GlcAT-P and HNK-1ST fusion protein is as shown in SEQ ID NO. 1; the kit can be used for detecting the MAG autoantibody, has excellent detection sensitivity and specificity, and can ensure the detection accuracy especially for the detection in a low titer range.

A bispecific or dual target CAR or CAR-T cells can be used to treat and / or prevent an autoimmune disease. The bispecific CAR may target CD19 and BCMA. The CAR may have a loop structure, which is shown as follow: L-VL, CD19-VH, BCMA-VL, BCMA-VH, CD19-H-TM-C-CD3ζ; the BCMA-CD19 CAR-T cells transduced by the chimeric antigen receptor targeting CD19 and BCMA can completely block the pathway of producing autoantibodies, and completely cover the B cells, plasmablasts and plasma cells at multiple differentiation stages that produce autoantibodies, so that the dual-target CAR-T therapy designed based on this concept can be aimed at refractory SLE and is expected to achieve faster remission and deeper and lasting curative effect.

The invention relates to an antibody detection kit for neuroparatoma syndrome and a preparation method of the antibody detection kit. The antibody detection kit for neuroparatoma syndrome comprises an antibody detection strip, a cleaning solution, a buffer solution and an auxiliary agent, wherein the antibody detection strip is a nitrocellulose membrane which is coated with antigen proteins containing Amphiphysin, CV2, GAD65, Hu, PNMA2 (Ma2 / Ta), Recovery, Ri, SOX1, Titin, Tr (DNER), Yo and Zic4. The invention further discloses a detection method of the antibody detection strip. The antibody detection kit disclosed by the invention can be used for simultaneously detecting 12 autoantibodies related to the neuroparatoma syndrome. The design of simultaneous detection of multiple antibodies greatly improves the comprehensiveness of detection, so that multiple possible pathogenic factors can be covered in single detection, the kit can be used for differential diagnosis of suspected neuroparatoma syndrome patients in professional laboratories, and the problem of missed diagnosis caused by single antibody detection is avoided.

The present invention relates to autoantibodies against NaV1.5 channel, their use as biomarker for the diagnosis of Brugada syndrome in human beings and relative methods of detection and therapeutic approach to target this new discovered form of autoimmunity.

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor (BCR), polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells (e.g., T cells) comprising the CAAR, wherein the CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7). The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7).

The disclosure describes compounds of Formula (I) and Formula (II), which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-β1AR binding moiety. Compounds of Formula (I) and Formula (II) are useful in preventing, treating and / or ameliorating heart failure in a subject when administered therapeutically effective amounts.

The present invention relates to RyR1 antigens, antigen expression genes, antigen expression vectors, cell lines and uses. The present invention provides two effective antigens for detecting anti-RyR1 autoantibodies: MGTR1 and MGTR2, which have the characteristics of small molecule size and good expression. Expression plasmids carrying the MGTR1 and MGTR2 genes are transfected into cell lines to prepare cell-based detection materials. The prepared detection materials have good sensitivity, specificity and stability for RyR1 antibodies. The indirect immunofluorescence method using cells is used to screen for anti-RyR1 autoantibodies in MG patients and MG patients with thymoma. Based on the RyRl cell detection matrix material, a two-color fluorescence system is adopted, and its co-localization effect is good. Therefore, it has good sensitivity, specificity and stability. The RyR1 cell detection matrix of the present invention can meet the needs of auxiliary clinical diagnosis.

The present disclosure provides systems and methods for detecting anti-NMDAR autoantibodies based on the strong affinity of the anti-NMDAR autoantibodies to a plurality of non-random anti-NR1s coupled to a solid support. The present disclosure also provides methods of treatment for anti-NMDAR pathology by the therapeutic anti-NMDAR antibody ART5803. The present disclosure also provides methods and systems for screening and predicting potential responsiveness to ART5803 therapy.

The invention relates to an antibody detection kit for detecting chronic inflammatory demyelinating multiple nerve root neuropathy and a preparation method of the antibody detection kit. The antibody detection kit for detecting the chronic inflammatory demyelinating multiple nerve root neuropathy comprises an IgG antibody detection strip, an IgM antibody detection strip, a working solution and an auxiliary agent. The antibody detection kit disclosed by the invention can be used for simultaneously detecting nine autoantibodies related to the chronic inflammatory demyelinating multiple nerve root neuropathy, wherein the nine autoantibodies comprise NF155, NF186, CNTN1, CNTN2, CASPR1, CASPR2, GLIOMEDIN, NRCAM and MAG. The design of simultaneous detection of multiple antigens greatly improves the comprehensiveness of detection, so that multiple possible pathogenic factors can be covered in single detection, and the problem of missed diagnosis caused by single antibody detection is avoided.

The invention belongs to the field of immune cell therapy, and particularly relates to application of a double-target CAR-T cell to treatment of systemic lupus erythematosus and other B-cell autoimmune diseases. A first target point of the chimeric antigen receptor is CD19, a second target point of the chimeric antigen receptor is BCMA, and the chimeric antigen receptor with the Loop structure is specifically the chimeric antigen receptor with the Loop structure, and the structure of the chimeric antigen receptor with the Loop structure is shown as follows: L-VL, CD19-VH, BCMA-VL, BCMA-VH and CD19-H-TM-C-CD3zeta; the BCMA-CD19 CAR-T cell transduced by the chimeric antigen receptor can more comprehensively block the way of generating the autoantibody in the process of targeting CD19 and BCMA, and can more completely cover B cells, plasma mother cells and plasma cells which generate the autoantibody and are in a plurality of differentiation stages; therefore, the double-target CAR-T therapy designed on the basis of the concept can be used for treating refractory SLE, and is expected to obtain quicker relieving and deeper and lasting curative effects.

The invention relates to the technical field of liquid phase chips, in particular to an autoantibody spectrum detection platform based on a liquid phase chip technology, and the method comprises the following steps: preparation and functionalization of quantum dot encoding microspheres; the core-shell structure quantum dots are used as coding elements, and fluorescence coding combination of more than 1000 is realized by regulating and controlling the size, 3-10nm, Mn < 2 + > doping and spatial distribution of the quantum dots. The method has the advantages of super multi-target detection, super sensitivity, strong anti-interference capability and intelligent analysis, in the actual process, the core-shell structure quantum dots are adopted as coding elements, more than 1000 fluorescent coding combinations are realized by regulating and controlling the size, doping and spatial distribution of the quantum dots, high-density coding is realized by utilizing three-parameter coding and an orthogonal decoupling algorithm, and the method is suitable for large-scale industrial production. More types of autoantibodies can be detected at the same time, so that the detection flux is improved; the surfaces of the quantum dots are coated with silicon dioxide layers, and the fluorescence intensity is attenuated by lt under continuous laser irradiation; and the stability of a fluorescence signal in the detection process is ensured.

The invention provides a nasopharynx cancer antibody marker and application thereof. Specifically, the invention provides application of the nasopharyngeal carcinoma antibody marker or the detection reagent thereof, the nasopharyngeal carcinoma antibody marker or the detection reagent thereof is used for preparing a diagnostic reagent or a diagnostic kit, and the diagnostic reagent or the diagnostic kit is used for judging the occurrence risk of nasopharyngeal carcinoma. The nasopharyngeal carcinoma antibody marker comprises the following antibody combination: (B) an EBV antibody; (B1) BKRF1-IgA; (B2) BMRF1 (BMRF1-IgA); and (B3) a BALF2-IgA, and (B4) a And (A) an autoantibody comprising any one of the autoantibodies selected from the group consisting of: (A1) anti-TPI1, or a combination thereof; (A2), anti-PRKACA (Pseudomonas And (A3) an anti-TRIM21 (Triglyceride- The nasopharyngeal carcinoma antibody marker can be used as a marker for judging nasopharyngeal carcinoma, and has high sensitivity and specificity.

A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine / adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

The embodiment of the invention discloses an angiotensin II-1 type receptor polypeptide or a fusion compound and application of the angiotensin II-1 type receptor polypeptide or the fusion compound. The invention provides an angiotensin type 1 receptor polypeptide or fusion, which is coated in a solid phase material (porous plate, magnetic beads, agarose particles, latex particles and the like) and is used for detecting an antibody aiming at an angiotensin II-1 receptor in the body of a patient suffering from diseases such as eclampsia and the like. The compound can also be used for blocking the combination of autoantibodies in the bodies of pregnant women and angiotensin II-1 type receptors, and treating various cardiovascular diseases such as dilated cardiomyopathy, just-gauge disease, heart failure and the like.

Compositions comprising a fragment of a first human receptor target of myasthenia gravis autoantibodies or an analog or derivative thereof and a fragment of a second human protein receptor of myasthenia gravis autoantibodies or an analog or derivative thereof are provided. Pharmaceutical compositions comprising the composition, nucleic acid systems encoding the polypeptides of the composition and methods of treatment and determining suitability for treatment using the composition; as well as methods of producing the composition are also provided.

The invention discloses a novel compound and application thereof in preparation of a medicine for treating systemic lupus erythematosus. In-vitro experiments show that the compound provided by the invention can further inhibit the secretion of anti-dsDNA IgG + B cell subtype mediated autoantibody by inhibiting the process that B cells are differentiated into plasmoblasts; in-vivo experiments show that the compound provided by the invention can effectively reduce the content of total IgG and anti-dsDNA-IgG in peripheral blood of a systemic lupus erythematosus model mouse, inhibit splenomegaly and peripheral lymph node hyperplasia of the mouse, slow down urine protein increment of the mouse, inhibit glomerular lesion and renal tubule lesion of the mouse and inhibit IFN-gamma generation of the mouse kidney; differentiation of spleen and peripheral lymph node plasmablasts of mice is inhibited, that is, differentiation and function development (antibody secretion) processes of B cells are directly acted. Therefore, the compound provided by the invention has a prospect of being developed into drugs for treating systemic lupus erythematosus.

The invention belongs to the technical field of autoimmune skin disease immunotherapy, and provides a three-target novel chimeric autoantibody receptor structure which comprises three chimeric receptors through two connecting peptides, specifically, a first chimeric autoantibody receptor comprises a Dsg1 extracellular structural domain; the second chimeric autoantibody receptor comprises a Dsg3 extracellular structural domain; the third chimeric antigen receptor comprises an extracellular domain capable of targeting a B cell associated antigen; wherein the Dsg1 extracellular structural domain is an extracellular structural domain of desmosome core glycoprotein 1; the Dsg3 extracellular structural domain is the extracellular structural domain of desmosome core glycoprotein 3. In-vitro experiments and animal experiments verify that the novel three-target CAAR-T cells can significantly increase the release of cytokines, enhance the targeted killing activity of the cytokines, and show better multiplication capacity; a novel cellular immunotherapy technology is provided for treating autoimmune skin diseases, and the application of CAAR-T in the field of autoimmune disease treatment can be expanded.

The invention relates to a method for screening tumor autoantibodies by using a small peptide display library. The method comprises the following steps: S1, obtaining a tumor mutation small peptide display library; s2, screening to obtain small peptides capable of interacting with serum; s3, analyzing protein and mutation information in the tumor mutation material to obtain an analysis result; and S4, calculating to obtain protein and mutation information with significant difference. Therefore, on the basis of obtaining a tumor mutation material (related), serum immunoprecipitation and high-throughput sequencing are combined, and a strategy for globally and unbiasedly researching the mutation-related tumor autoantibody is provided.

The present disclosure provides methods of treating an alloimmune or autoimmune disorder in an individual; the methods involve administering to the individual an effective amount of an antibody specific for complement component C1s. The present disclosure provides a method of monitoring the efficacy of a subject treatment method; the method involves detecting the level of autoantibody or alloantibody in a biological sample obtained from the individual.

To provide a biomarker, a diagnostic kit, and a method of assisting in diagnosis for the specific diagnosis of a group having specific disease state physiology in acute and chronic inflammatory demyelinating peripheral neuropathy with unknown autoantibody.SOLUTION: There are provided a biomarker, a diagnostic kit containing the same, and a method of assisting in diagnosis for using the same for diagnosis of inflammatory demyelinating polyneuropathy, including anti-LGI4 antibodies, or for determination of the efficacy of treatment, or the inflammatory demyelinating polyneuropathy being an autoimmune neuropathy.SELECTED DRAWING: None

Systems and methods for the identification of auto-antibodies associated with central nervous system or psychiatric disease or disorders. Also disclosed herein are methods of treating central nervous system or psychiatric disease or disorders associated with auto-antibodies.

The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present disclosure provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment and / or management of a disease and / or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and / or disorder. In certain embodiments, the circulating protein is TNF.